[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
October 13, 2015

New Therapies in the Treatment of High CholesterolAn Argument to Return to Goal-Based Lipid Guidelines

Author Affiliations
  • 1CVS Health, Woonsocket, Rhode Island
JAMA. 2015;314(14):1443-1444. doi:10.1001/jama.2015.10017

On July 25, the US Food and Drug Administration (FDA) approved alirocumab (Praluent), the first in a new class, the proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors. Approval of a second medication in the class is expected shortly. The injected medications are used to treat patients with hyperlipidemia, and early results suggest these drugs have a powerful effect on levels of low-density lipoprotein cholesterol (LDL-C), likely more potent than statins.1 Although evidence continues to accumulate, the class appears to represent an important new development in hyperlipidemia management.

First Page Preview View Large
First page PDF preview
First page PDF preview
×